Include These Biotech Stocks In Your Retirement Portfolio

Summary I look at three biotech stocks that even conservative investors can include in their retirement portfolio. All three stocks have beta lower than the average for the biotech sector. Gilead, Amgen and Regeneron are the three top picks for retirement portfolio. The biotech sector is generally seen as riskier than most other sectors when it comes to investing in equities. According to data from Stern, the biotech sector has an unlevered beta of 1.02, which is above the unlevered beta for the total market (0.67). In non-financial language, this means that the biotech sector offers a higher rate of return than the market but also poses more risk. When creating a portfolio for retirement, most investors want to minimize the risk while generating steady returns. The idea is to see some capital appreciation and at the same time generate steady income by investing in low beta, dividend paying stocks. Therefore many retirement portfolios exclude biotech sector completely. That is a big mistake. The risk in the biotech sector is mostly constituted in the small and mid-cap space. Most companies in these space are either in development stage or have just reached commercialization stage. Also many of these companies have just one or two drugs in their pipeline and therefore the chances of failure are higher. Certainly, conservative investors should stay away from these. But there are other opportunities, mainly in the large cap space, where even conservative investors can gain exposure. I will be highlighting a few biotech stocks that even conservative investors should consider including in their retirement portfolio. Gilead Sciences (NASDAQ:GILD) Regular readers of my articles here on Seeking Alpha would be well aware that I have been extremely bullish on Gilead Sciences for over the past year or so. The reason is simple. Gilead, unlike the general perception, is not a one-trick pony. The company has two successful franchises, both in the antiviral area. GILD's HCV franchise has seen phenomenal success since the launch of Sovaldi almost two years ago. In fact, its the huge success of HCV drugs that has created the image that GILD is heavily reliant on just its HCV drugs. But there is the HIV franchise as well, which is seeing robust growth and with the introduction of TAF-based products is going to maintain its dominance in the multi-billion dollar HIV treatment market. What I have always admired about Gilead is its proactive approach. For example, the company has been proactive in bringing its TAF-based products to the market. Gilead has been a dominant player in the HIV space for many years, however, this dominance was challenged by Triumeq. The introduction of the TAF-based products will allow GILD to not only maintain its market share but even win back some share from Triumeq. Another example of GILD's proactiveness is the company's strengthening of its HCV franchise. Then there are other exciting areas where Gilead has a presence. One of them is NASH. Gilead already has products in its pipeline targeting what could be a $40 billion market. And the company raised $10 billion in a debt offering earlier this year, which it is likely to use to acquire late-stage development assets most likely in the liver space where it already has significant presence through its HCV drugs. Gilead certainly has the drivers for future growth, which in my opinion will lead to significant capital appreciation in the next four to five years. To add to this, GILD is an extremely shareholder friendly company. On the back of the success of its HCV franchise, GILD has announced share buybacks and also pays regular quarterly dividend, both uncommon for growth stage companies which Gilead is despite the fact it already has a market cap of almost $150 billion. Gilead has a beta of 0.82, which is lower than the average for the biotech sector. Even in a year that seen the biotech sector come under pressure, GILD has managed to generate returns of nearly 9.90%. Amgen (NASDAQ:AMGN) Amgen is another solid large cap biotech company that offers a higher rate of return than the market in the long term but has a beta below 1. AMGN's beta is 0.73, lower than GILD's and well below the average for the biotech sector. AMGN's beta is in fact closer to the average for the total market. Low volatility, however, does not mean low returns. Over the last five years, AMGN has returned more than 188%. Earlier this month, AMGN announced a 27% hike in its quarterly dividend. As a result of the dividend hike, AMGN now offers a dividend yield of 2.45%. The yield is not the most attractive but remember that AMGN offers substantial capital appreciation over the next four to five years. The current consensus forecast for 2016 revenue is at $22.28 billion. Based on this estimate, AMGN currently trades at around 5.5x sales. This is below the industry average of 10x sales, according to data from Stern. There is at least 30%-40% upside in AMGN in the next two to three years, in my opinion. One of the value drivers for Amgen will be its PCSK9 inhibitor, Repatha. Repatha is expected to be a blockbuster drug despite competition. Regeneron (NASDAQ:REGN) The competition to AMGN's Repatha is going to come from Regenron and Sanofi's (NYSE:SNY) Praluent. Praluent is also expected to be a blockbuster drug for REGN and Sanofi. Recently, Praluent was selected by UnitedHealth Group for preferred access its formularies, which include OptumRx and UnitedHealthcare Commercial. Praluent is now accessible to more than 100 million patients in the U.S. One of the concerns before the launch of Praluent, as well as Repatha, was that PBMs might shun them because of their pricing. However, both Amgen and REGN have managed to strike deals with PBMs since launch. REGN is also seeing robust growth for its EYLEA Injection. In the third quarter of 2015, REGN saw a 53% increase in EYLEA Injection global net sales. In the U.S. alone, the company generated $734 million in sales. Total EYLEA sales exceeded $1 billion. Among the three stocks I have discussed in this article, REGN is the most expensive, trading at forward P/E of 35.97 compared to 15.35 for AMGN and 8.68 for GILD. Also unlike GILD and AMGN, REGN currently does not offer any dividend payments. Also it has a slightly higher beta (0.96) than the other two. But REGN has the potential to nearly double from current levels even if the company maintains steady revenue growth of 20% over the next five years. REGN's revenue should exceed $10 billion by the end of this decade if it maintains 20% growth over the next five years. Maintaining this level of growth over the next five years will not be difficult considering the potential of Praluent and how EYLEA sales have evolved. In fact, the sales forecast might turn out to be conservative. But even based on it and the average price to sales multiple of 10x, I get a price per share of $1000 for REGN. [...]

By |December 30th, 2015|SA Archive|0 Comments

Bio Blast’s Change In Trial Strategy – Anything To Worry About?

Summary On October 27, post excellent reported interim results, Bio Blast announced the postponement of its phase 2 trial as redundant, and an early start of phase 3. On December 9, ORPN changed its stance, rescheduled phase 3, and started a phase 2b trial. Is this a cause of worry? [...]

By |December 18th, 2015|SA Archive|0 Comments

Geron’s ASH Presentations: What We Heard

Summary Geron made two oral presentations and one poster presentation at ASH 2015. Data showed excellent results in ET patients with various mutations, and some progress in MF patients. This article discusses that data. Geron (NASDAQ:GERN) shares traded above $5 for the first time in a long time after the [...]

By |December 16th, 2015|SA Archive|0 Comments

What I Like About Genocea

Summary Genocea is a small cap with an interesting platform for vaccine development. Developed at Harvard, the ATLAS platform is the long-term value driver for the company. Its immediate value is in GEN-003, a vaccine being developed for the HSV-2 virus. Note - Complete valuation is available to my subscribers [...]

By |December 12th, 2015|SA Archive|0 Comments

Bluebird Bio: Waiting For Sickle Cell Disease Data

Summary BLUE fell 20% after mixed Northstar data. But SCD is the larger market than beta-thalassemia major. BLUE has one solid patient result so far in SCD, and is enrolling more patients in the trial. (Check my profile for my real time biotech trade alerts services for those who want [...]

By |November 18th, 2015|SA Archive|0 Comments

Anavex: Response To 3 Recent Bearish Articles

Summary This article refutes the science-related claims of Mr Adam Feuerstein using expert opinions from interviews. The donepezil-2-73 differential effect is the most important statement to come out of any Alzheimer's trial in recent memory. This article denies that that effect is a placebo effect. First, a brief history. I [...]

By |November 18th, 2015|SA Archive|0 Comments

Anavex: Interview With Professor Tangui Maurice

Summary Doctor Tangui Maurice is a professor at Montpellier University. He is a co-discoverer of ANAVEX 2-73 and a well-regarded authority on sigma 1r pharmacology. In this interview, he discusses the latest trial of ANAVEX 2-73, among other things. This email interview with Professor Tangui Maurice, done over the weekend [...]

By |November 18th, 2015|SA Archive|0 Comments

Anavex Life Sciences: Interview With Dr. Stephen Macfarlane

Summary Anavex has seen a huge sell-off since last Friday. The sell-off has come even as data released from the Phase 2a trial was satisfactory. I interviewed Dr. Stephen Macfarlane, the trial's investigator, about the data. Anavex Life Sciences (NASDAQ:AVXL) shares are down more than 30% today. The stock has [...]

By |November 12th, 2015|SA Archive|0 Comments

Merrimack’s Onivyde Could Be A Game Changer

Summary Merrimack’s Onivyde was approved recently. The black box warning will not have an impact on Onivyde sales. Merrimack’s current valuation does not reflect Onivyde’s potential. A lot of research in the current global pipeline scenario is focused on life-extending drugs for cancer. If successful, these drugs are likely to [...]

By |November 6th, 2015|SA Archive|0 Comments

Zafgen: Embattled, Beleaguered, High-Risk, But Considerable Upside Nevertheless

Summary Zafgen's partial clinical hold has made it lose more than half its market cap in a few days. If things go smoothly, this itself presents a high-risk, high-reward opportunity, considering beloranib's efficacy. If things go downhill, the stock is trading about $3 above its cash per share. Zafgen (NASDAQ:ZFGN) [...]

By |October 25th, 2015|SA Archive|0 Comments

Anavex Is Not Some Scam Company; It Has Believable Science

Summary This article is a response to a recent bearish Anavex article on SeekingAlpha. It is also some amount of research put together to justify my belief in the science behind Anavex. Anavex may succeed, or it may fail, but it has a novel approach to Alzheimer's that should be [...]

By |October 25th, 2015|SA Archive|0 Comments

Eli Lilly: Jardiance’s Potential Softens The Blow

Summary Eli Lilly terminated the development of evacetrapib this week. Eli Lilly shares tumbled on the news. The bad news comes shortly after the company’s positive Jardiance data. Eli Lilly (NYSE:LLY) tumbled earlier this week after the company announced that it has terminated the development of its cardiovascular drug evacetrapib. [...]

By |October 16th, 2015|SA Archive|0 Comments

Heat Biologics Has Considerable Upside In Cancer Immunotherapy

Summary Heat Biologics is combining its HS-110 with Opdivo in a new trial. Its ImPACT platform has advantages over other antigen-specific immunotherapy platforms. If HS-110 succeeds in trial, the company has considerable upside. Here's an interesting story from a pioneering small company: Heat Biologics (NASDAQ:HTBX). Last year, HTBX was developing [...]

By |October 11th, 2015|SA Archive|0 Comments

Biotech Sell-Off: Temporary, Or Here To Stay?

Summary The correction has been steeper. Funds are selling, high frequency traders are selling. But disease is still the same disease, germs are still the same germs - if not worse. Nothing is going to change the fundamental truth about medicines - that most of them are necessities, while some [...]

By |October 10th, 2015|SA Archive|1 Comment

The Science and The Logic of Biotech Acquisitions – Part 1

Gilead's Next Logical Acquisition, Part 1: NASH And Galmed At the Morgan Stanley Global Healthcare Brokers Conference held recently, Gilead Sciences (NASDAQ:GILD) said that it wants to acquire assets that will be complementary to its internal programs. So that got me thinking: What canGilead acquire? In HIV, there's nothing to [...]

By |October 8th, 2015|SA Archive|2 Comments

Portola: Who’s Afraid Of Praxbind?

Summary Portola went down 9% after CHMP's recommendation of Praxbind, and may go down further. Praxbind is an antidote for Pradaxa while Portola is developing an antidote for Xarelto and Eliquis. This is an opportunity to buy PTLA, because my investment thesis in unchanged, but the market is underestimating the [...]

By |September 30th, 2015|SA Archive|0 Comments

Bio Blast – Small Company With Multiple Interesting Orphan Drug Platforms

Summary Bio Blast is a small Israeli company with 3 interesting drug platforms. These platforms target rare genetic disorders, and its Cabaletta has 2 ODDs and one FT designation. If successful, ORPN has 40% upside to current levels. Bio Blast Pharma (NASDAQ:ORPN) is a small company targeting some rare diseases [...]

By |September 26th, 2015|SA Archive|0 Comments

Actinium: Possible Upside In Radioimmunotherapy Despite Stock Promotion And Dilution Issues

Summary Actinium is a small company, but has excellent deals with well-known research institutes. Its two products in radioimmunotherapy have both shown considerable promise. If the promise is delivered, then my conservative estimate gives considerable upside. ATNM has dilution and stock promotion issues. Actinium (NYSEMKT:ATNM) is a company with a [...]

By |September 6th, 2015|SA Archive|0 Comments

Arrowhead: Ignoring The Street Would Serve Investors Well

Summary Arrowhead provided details on its clinical trials during Q2 conference call. The company once again emphasized that ARC-520 was never intended to be a single-dose therapy. Wall Street seems to be once again creating false expectations ahead of Analyst Day. Arrowhead (NASDAQ:ARWR) reported its second-quarter financial results after market [...]

By |August 8th, 2015|SA Archive|0 Comments

Regeneron Pharmaceuticals: 2 More Factors That Could Boost Stock Price

Summary Regeneron shares rose to an all-time high level, driven by strong Q2 results and guidance. Regeneron could see further upside based on just fundamentals. The company is moving closer to a stage where it might consider returning some cash to shareholders, which will boost returns. A stock split could [...]

By |August 7th, 2015|SA Archive|0 Comments
s2Member®